Reuters logo
BRIEF-Argenx reaches 50 pct enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis
May 4, 2017 / 5:35 AM / 7 months ago

BRIEF-Argenx reaches 50 pct enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis

May 4 (Reuters) - Argenx Nv:

* Argenx NV - has recruited 50 pct of myasthenia gravis (mg) patients in phase 2 proof-of-concept study of argx-113 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below